-
1
-
-
84896698734
-
-
American Cancer Society, Cancer Facts & Figures 2013. Accessed on November 11, 2013
-
American Cancer Society, Cancer Facts & Figures 2013. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-036845.pdf. Accessed on November 11, 2013.
-
-
-
-
2
-
-
0028084421
-
Patterns of failure following surgical resection of renal cell carcinoma: Implications for adjuvant local and systemic therapy
-
Rabinovich RA, Zelefsky MJ, Gaynor JJ, Fuks Z,. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol. 1994; 12: 206-212.
-
(1994)
J Clin Oncol.
, vol.12
, pp. 206-212
-
-
Rabinovich, R.A.1
Zelefsky, M.J.2
Gaynor, J.J.3
Fuks, Z.4
-
3
-
-
0344442746
-
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease
-
Janzen NK, Kim HL, Figlin RA, Belldegrun HA,. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003; 30: 843-852.
-
(2003)
Urol Clin North Am.
, vol.30
, pp. 843-852
-
-
Janzen, N.K.1
Kim, H.L.2
Figlin, R.A.3
Belldegrun, H.A.4
-
4
-
-
33846821872
-
Targeted therapy for metastatic renal cell carcinoma
-
Motzer RJ, Bukowki RM,. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol. 2006; 24: 5601-5608.
-
(2006)
J Clin Oncol.
, vol.24
, pp. 5601-5608
-
-
Motzer, R.J.1
Bukowki, R.M.2
-
5
-
-
0042343801
-
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cell carcinoma
-
Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cell carcinoma. N Engl J Med. 2003; 349: 427-434.
-
(2003)
N Engl J Med.
, vol.349
, pp. 427-434
-
-
Yang, J.C.1
Haworth, L.2
Sherry, R.M.3
-
6
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124.
-
(2007)
N Engl J Med.
, vol.356
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
7
-
-
33846148701
-
Sorafenib in advanced renal-cell carcinoma
-
Escudier B, Eisen T, Stadler WM, et al; TARGET Study Group. Sorafenib in advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 125-134.
-
(2007)
N Engl J Med.
, vol.356
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
-
8
-
-
35148857486
-
Sunitinib efficacy against advanced renal cell carcinoma
-
Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol. 2007; 178: 1883-1887.
-
(2007)
J Urol.
, vol.178
, pp. 1883-1887
-
-
Motzer, R.J.1
Michaelson, M.D.2
Rosenberg, J.3
-
9
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors
-
European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
-
(2000)
J Natl Cancer Inst.
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
10
-
-
84882781441
-
Pazopanib versus sunitinib in metastatic renal-cell carcinoma
-
Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013; 369: 722-731.
-
(2013)
N Engl J Med.
, vol.369
, pp. 722-731
-
-
Motzer, R.J.1
Hutson, T.E.2
Cella, D.3
-
11
-
-
77953341948
-
Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib
-
Thiam R, Fournier LS, Trinquart L, et al. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol. 2010; 21: 936-941.
-
(2010)
Ann Oncol.
, vol.21
, pp. 936-941
-
-
Thiam, R.1
Fournier, L.S.2
Trinquart, L.3
-
12
-
-
77649272736
-
Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
-
van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Haanen JB, Boven E,. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer. 2010; 102: 803-809.
-
(2010)
Br J Cancer.
, vol.102
, pp. 803-809
-
-
Van Der Veldt, A.A.1
Meijerink, M.R.2
Van Den Eertwegh, A.J.3
Haanen, J.B.4
Boven, E.5
-
13
-
-
74749099130
-
Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: Importance of size and attenuation on contrast-enhanced CT
-
Smith AD, Lieber ML, Shah SN,. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol. 2010; 194: 157-165.
-
(2010)
AJR Am J Roentgenol.
, vol.194
, pp. 157-165
-
-
Smith, A.D.1
Lieber, M.L.2
Shah, S.N.3
-
14
-
-
77953236472
-
Morphology, Attenuation, Size and Structure (MASS) criteria: Assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy
-
Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM,. Morphology, Attenuation, Size and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol. 2010; 194: 1470-1478.
-
(2010)
AJR Am J Roentgenol.
, vol.194
, pp. 1470-1478
-
-
Smith, A.D.1
Shah, S.N.2
Rini, B.I.3
Lieber, M.L.4
Remer, E.M.5
-
15
-
-
79953247379
-
Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma
-
Krajewski KM, Guo M, Van den Abbeele AD, et al. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol. 2011; 59: 856-862.
-
(2011)
Eur Urol.
, vol.59
, pp. 856-862
-
-
Krajewski, K.M.1
Guo, M.2
Van Den Abbeele, A.D.3
-
16
-
-
84866752296
-
Course and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy
-
Hittinger M, Staehler M, Schramm N, et al. Course and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy. Urol Oncol. 2012; 30: 695-703.
-
(2012)
Urol Oncol.
, vol.30
, pp. 695-703
-
-
Hittinger, M.1
Staehler, M.2
Schramm, N.3
-
17
-
-
84878618268
-
Choi response for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies
-
Schmidt N, Hess V, Zumbrunn T, et al. Choi response for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies. Eur Radiol. 2013; 23: 632-639.
-
(2013)
Eur Radiol.
, vol.23
, pp. 632-639
-
-
Schmidt, N.1
Hess, V.2
Zumbrunn, T.3
-
18
-
-
34249085905
-
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria
-
Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007; 25: 1753-1759.
-
(2007)
J Clin Oncol.
, vol.25
, pp. 1753-1759
-
-
Choi, H.1
Charnsangavej, C.2
Faria, S.C.3
-
19
-
-
0024521543
-
A concordance correlation coefficient to evaluate reproducibility
-
Lin LI,. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989; 45: 255-268.
-
(1989)
Biometrics.
, vol.45
, pp. 255-268
-
-
Lin, L.I.1
-
20
-
-
84908219488
-
Statistical methods for assessing agreement between two methods of clinical measurement
-
Bland JM, Altman DG,. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986; 1: 307-310.
-
(1986)
Lancet.
, vol.1
, pp. 307-310
-
-
Bland, J.M.1
Altman, D.G.2
-
21
-
-
67650085792
-
Evaluating variability in tumor measurements from same-day repeat CT scans of patients with nonsmall cell lung cancer
-
Zhao B, James LP, Moskowitz CS, et al. Evaluating variability in tumor measurements from same-day repeat CT scans of patients with nonsmall cell lung cancer. Radiology. 2009; 252: 263-272.
-
(2009)
Radiology.
, vol.252
, pp. 263-272
-
-
Zhao, B.1
James, L.P.2
Moskowitz, C.S.3
-
22
-
-
78649905395
-
CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool
-
Nishino M, Guo M, Jackman DM, et al. CT tumor volume measurement in advanced non-small-cell lung cancer: performance characteristics of an emerging clinical tool. Acad Radiol. 2011; 18: 54-62.
-
(2011)
Acad Radiol.
, vol.18
, pp. 54-62
-
-
Nishino, M.1
Guo, M.2
Jackman, D.M.3
-
23
-
-
84973587732
-
A coefficient of agreement for nominal scales
-
Cohen J,. A coefficient of agreement for nominal scales. Educ Psychol Measure. 1960; 20: 37-46.
-
(1960)
Educ Psychol Measure.
, vol.20
, pp. 37-46
-
-
Cohen, J.1
-
24
-
-
0038352143
-
Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: Implications for assessment of tumor response
-
Erasmus JJ, Gladish GW, Broemeling L, et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol. 2003; 21: 2574-2582.
-
(2003)
J Clin Oncol.
, vol.21
, pp. 2574-2582
-
-
Erasmus, J.J.1
Gladish, G.W.2
Broemeling, L.3
-
25
-
-
0037388483
-
Tumour size measurement in an oncology clinical trial: Comparison between off-site and on-site measurements
-
Belton AL, Saini S, Liebermann K, Boland GW, Halpern EF,. Tumour size measurement in an oncology clinical trial: comparison between off-site and on-site measurements. Clin Radiol. 2003; 58: 311-314.
-
(2003)
Clin Radiol.
, vol.58
, pp. 311-314
-
-
Belton, A.L.1
Saini, S.2
Liebermann, K.3
Boland, G.W.4
Halpern, E.F.5
-
26
-
-
77949319026
-
Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials
-
Tang PA, Pond GR, Chen EX,. Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials. Ann Oncol. 2010; 21: 19-25.
-
(2010)
Ann Oncol.
, vol.21
, pp. 19-25
-
-
Tang, P.A.1
Pond, G.R.2
Chen, E.X.3
-
27
-
-
77951249058
-
Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria
-
Suzuki C, Torkzad MR, Jacobsson H, et al. Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria. Acta Oncol. 2010; 49: 509-514.
-
(2010)
Acta Oncol.
, vol.49
, pp. 509-514
-
-
Suzuki, C.1
Torkzad, M.R.2
Jacobsson, H.3
-
28
-
-
84863857730
-
Observer variability in a phase II trial-assessing consistency in RECIST application
-
Skougaard K, McCullagh MJ, Nielsen D, Hendel HW, Jensen BV, Johannesen HH,. Observer variability in a phase II trial-assessing consistency in RECIST application. Acta Oncol. 2012; 51: 774-780.
-
(2012)
Acta Oncol.
, vol.51
, pp. 774-780
-
-
Skougaard, K.1
McCullagh, M.J.2
Nielsen, D.3
Hendel, H.W.4
Jensen, B.V.5
Johannesen, H.H.6
-
29
-
-
84858252503
-
Intra- and inter-observer variability in measurement of target lesions: Implication on response evaluation according to RECIST 1.1
-
Muenzel D, Engels HP, Bruegel M, Kehl V, Rummeny EJ, Metz S,. Intra- and inter-observer variability in measurement of target lesions: implication on response evaluation according to RECIST 1.1. Radiol Oncol. 2012; 46: 8-18.
-
(2012)
Radiol Oncol.
, vol.46
, pp. 8-18
-
-
Muenzel, D.1
Engels, H.P.2
Bruegel, M.3
Kehl, V.4
Rummeny, E.J.5
Metz, S.6
-
30
-
-
80051725760
-
Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes
-
Oxnard GR, Zhao B, Sima CS, et al. Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J Clin Oncol. 2011; 29: 3114-3119.
-
(2011)
J Clin Oncol.
, vol.29
, pp. 3114-3119
-
-
Oxnard, G.R.1
Zhao, B.2
Sima, C.S.3
-
31
-
-
0029769512
-
Analysis of interobserver and intraobserver variability in CT tumor measurements
-
Hopper KD, Kasales CJ, Van Slyke MA, Schwartz TA, TenHave TR, Jozefiak JA,. Analysis of interobserver and intraobserver variability in CT tumor measurements. AJR Am J Roentgenol. 1996; 167: 851-854.
-
(1996)
AJR Am J Roentgenol.
, vol.167
, pp. 851-854
-
-
Hopper, K.D.1
Kasales, C.J.2
Van Slyke, M.A.3
Schwartz, T.A.4
Tenhave, T.R.5
Jozefiak, J.A.6
-
32
-
-
0141925978
-
Variability in response assessment in solid tumors: Effect of number of lesions chosen for measurement
-
Schwartz LH, Mazumdar M, Brown W, Smith A, Panicek DM,. Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement. Clin Cancer Res. 2003; 9: 4318-4323.
-
(2003)
Clin Cancer Res.
, vol.9
, pp. 4318-4323
-
-
Schwartz, L.H.1
Mazumdar, M.2
Brown, W.3
Smith, A.4
Panicek, D.M.5
-
33
-
-
77956862485
-
New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: Comparison with original RECIST and impact on assessment of tumor response to targeted therapy
-
Nishino M, Jackman DM, Hatabu H, et al. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 2010; 195: W221-W228.
-
(2010)
AJR Am J Roentgenol.
, vol.195
-
-
Nishino, M.1
Jackman, D.M.2
Hatabu, H.3
-
34
-
-
57849117384
-
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
-
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247.
-
(2009)
Eur J Cancer.
, vol.45
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
|